Sue MacLeman has more than 30 years’ experience as a pharmaceutical, biotechnology and medical technology executive having held senior roles in corporate, medical, commercial and business development. Sue has also served as CEO and Board member of several ASX and NASDAQ listed companies in the pharmaceutical sector and is currently Chair of MTPConnect (MTPII-GC Ltd), Chair of Anatara Lifesciences Ltd (ASX:ANR), Tali Digital Ltd (ASX:TDI), Non-Executive Director of Palla Pharma Ltd (ASX:PAL), Non-Executive Director of Oventus Medical Ltd (ASX:OVN) and Non-Executive Director of veski. Sue is also appointed to several academic and government advisory committees, including CSIRO Health and Biosecurity Advisory Committee, Prime Ministers Digital Expert Advisory Committee, DMTC Medical Countermeasures and various COVID19 taskforces. Her broad commercial experience is underpinned by graduate qualifications in pharmacy and post graduate qualifications in corporate governance, commercial law, business administration and marketing.

Dr Andrea Douglas leads CSL’s Organisation Transformation Office, which integrates and drives major organisational design changes that have broad implications to the business across areas of strategy, structure, governance, process and people. She also leads government relations strategy in Australia.

Since 2005, Andrea has played key leadership roles in CSL’s progression to becoming Australia’s largest biotech, including leading global Research and Development (R&D) strategy, product portfolio, R&D investment and prioritisation processes as Vice President, R&D Strategy and External Affairs. She has also held roles as Vice President, Licensing, Head of Global R&D Project Management and Program Director, Influenza. Before joining CSL Andrea was the CEO of the Gene CRC, and also held a senior research role at WEHI. Andrea has a PhD in Forensic Medicine from Monash University, holds a Masters in Health Administration and is a graduate of the Australian Institute of Company Directors. She is a Director of the Baker Heart and Diabetes Institute and BioCurate, was a Director of AusBiotech from 2013-2019 and is currently a member of the Department of Jobs, Precincts and Regions Innovation Taskforce.

Andrea’s enormous impact is a direct result of her outstanding leadership. She has a strong research background, a strategic and pragmatic business mind, natural emotional intelligence, and a brilliant ability to communicate with people from diverse backgrounds. Andrea is particularly passionate about mentoring and supporting women in STEM, and has set herself apart as an outstanding role model for both work and life. As a leader, Andrea has an exceptional ability to advocate, persuade and support, enabling her to unite academia, industry and policy throughout the sector – a unique and valuable contribution with enormous impact.

Bronwyn Le Grice has over 18 years executive experience in the health technology sector spanning venture capital, transaction management, capital raising, corporate development, investor relations and industry advocacy. She commenced her health technology career with Neurosciences Victoria, and has worked across the life sciences and health technology sector in Australia and New Zealand since, including serving as Chief Executive Officer of NZBIO from 2008-2011. In 2012, Bronwyn joined BioScience Managers as an Investment Director, where she managed over $65M of private and public equity capital raisings, and in 2015 managed the largest digital health technology IPO on the ASX with the $35M listing of Adherium.

In 2016 Bronwyn developed the concept for a novel, digital health scale-up support program, alongside James Dromey of the Murdoch Children’s Research Institute, which she went on to found and lead as Managing Director. Now Australia’s leading health technology scale up accelerator, ANDHealth’s unique industry-led model has led to significant growth within Australia’s nascent digital health sector. Companies which have engaged in the flagship accelerator program developed by Bronwyn and delivered by the ANDHealth team have raised in excess of $28.7M in capital, created >165 jobs, undertaken 28 clinical trials and have served >70,000 patients, since 2017.

In 2019 Bronwyn completed her Masters of Commercial Law at Melbourne Law School, focusing on corporate governance and capital markets law. Bronwyn serves on a number of Advisory Committees for RMIT, Swinburne and La Trobe Universities and is a member of the Australia and New Zealand Leadership Forum Health Technologies Sector Group. Bronwyn brings an investment perspective into the innovation space, atypical to a sector dominated by technical thinking styles. She consistently backs herself and tenaciously pursues excellence in her work, inspiring others to do the same.

PhD in ageing Biology, Dr Ewa Douroux started her corporate career in scientific communication and medical affairs in Paris, primarily managing international advisory boards and experts. In 2008, Ewa moved to Sydney and to clinical research, where she led international trials for the pharmaceutical industry. After graduating from the INSEAD MBA, Ewa joined Leica Biosystems in early 2013 as Global Marketing Manager. In this role, Ewa was at the inception of a new smart and connected product line, allowing Leica to bridge a vitality gap between existing instruments and the forthcoming next generation platforms serving pathology laboratories around the world. In 2016 Ewa took the helm of the Contract Manufacturing Division, achieving a substantial transformation of the division through pragmatism, empathy, resilience and drive.

In early 2018 Ewa was asked to set up a new reagents production facility whilst also taking charge of Leica Melbourne Compliance and Environment, Health & Safety. In only a few months, Ewa was able to create a new dynamic and inspire others – including the launch of coordinated initiatives aimed at reducing the site’s carbon footprint by 15%. In late 2019 Ewa was appointed Asia Pacific Marketing Director, with the ambitious agenda to overhaul the marketing strategy, deliver revenue growth and contribute to the ongoing success of Leica Biosystems.

Ewa is passionate about how business can be a force for good and contribute to reducing our overall environmental footprint. She makes time to participate in the life of the biotech sector and is a generous contributor who is always happy to help and give her time to students, young entrepreneurs or professionals. She is invested in advancing diversity via cultural awareness and encouraging women in business. Ewa is a budding future industry leader, and a delightful person with a fabulous set of personal goals, ideals and values.